Tolterodine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Tolterodine
250px
Systematic (IUPAC) name
(R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol
Clinical data
Trade names Detrol
AHFS/Drugs.com monograph
MedlinePlus a699026
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
Pharmacokinetic data
Bioavailability 77%
Protein binding Approximately 96.3%.
Biological half-life 1.9-3.7 hours
Identifiers
CAS Number 124937-51-5 YesY
ATC code G04BD07 (WHO)
PubChem CID: 443879
IUPHAR/BPS 360
DrugBank DB01036 YesY
ChemSpider 391967 YesY
UNII WHE7A56U7K YesY
KEGG D00646 YesY
ChEBI CHEBI:9622 YesY
ChEMBL CHEMBL1382 YesY
Chemical data
Formula C22H31NO
Molecular mass 325.488 g/mol
  • Cc1ccc(c(c1)[C@H](CCN(C(C)C)C(C)C)c2ccccc2)O
  • InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1 YesY
  • Key:OOGJQPCLVADCPB-HXUWFJFHSA-N YesY
  (verify)

Tolterodine (Detrol, Detrusitol) is an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence.[1]

It is marketed by Pfizer in Canada and the United States by its brand name Detrol. In Egypt it is also found under the trade names Tolterodine by Sabaa and Incont L.A. by Adwia.

Use

Detrusor overactivity (DO, contraction of the muscular bladder wall) is the most common form of UI in older adults. It is characterized by uninhibited bladder contractions causing an uncontrollable urge to void. Urinary frequency, urge incontinence and nocturnal incontinence occur. Abnormal bladder contractions that coincide with the urge to void can be measured by urodynamic studies. Treatment is bladder retraining,[2] pelvic floor therapy or with drugs that inhibit bladder contractions such as oxybutinin and tolterodine.

Pharmacology

Tolterodine acts on M2 and M3 [3] subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors. It is marketed and manufactured by Pfizer.

Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.[citation needed]

Side effects of tolterodine

Known side effects:

The following reactions have been reported in patients who have taken tolterodine since it has become available:

Contraindications:

Not to be used in patients with myasthenia gravis and angle closure glaucoma.

References

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. Bladder retraining ichelp.org Interstitial Cystitis Association Accessed July 13, 2012
  3. [1] Archived November 26, 2012 at the Wayback Machine

External links